Compare SYM & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYM | CRSP |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.6B |
| IPO Year | N/A | 2016 |
| Metric | SYM | CRSP |
|---|---|---|
| Price | $59.42 | $56.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 19 |
| Target Price | $53.00 | ★ $71.50 |
| AVG Volume (30 Days) | ★ 4.4M | 1.9M |
| Earning Date | 02-04-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,246,922,000.00 | $38,337,000.00 |
| Revenue This Year | $21.90 | N/A |
| Revenue Next Year | $28.00 | $723.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 25.65 | N/A |
| 52 Week Low | $16.32 | $30.04 |
| 52 Week High | $87.88 | $78.48 |
| Indicator | SYM | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 50.34 |
| Support Level | $55.85 | $54.60 |
| Resistance Level | $63.89 | $58.00 |
| Average True Range (ATR) | 5.18 | 2.91 |
| MACD | -0.76 | 0.26 |
| Stochastic Oscillator | 14.20 | 59.23 |
Symbotic Inc is an automation technology company that develops technologies to improve operating efficiencies in modern warehouses. The group develops, commercializes, and deploys end-to-end technology solutions that dramatically improve supply chain operations. Th company also automates the processing of pallets and cases in large warehouses or distribution centers for some of the retail and wholesale companies in the world. The company operates in two geographical regions the United States and Canada. Key revenue is generated from the United States.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.